FIGURE 2.

She underwent 2 cycles with Lutathera, a radiolabeled somatostatin analog that has been shown to be an effective and safe treatment for somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors^5–7: 5.55 GBq in July 2013 and 7.4 GBq in September 2013. Figure 2 shows posttherapy ¹⁷⁷Lu-octreotate whole-body scans (A, first course, July 2013; B, second course, September 2013). A superior uptake than the baseline Octreoscan can be shown in the first ¹⁷⁷Lu-octreotate scan and additionally 2 implants upon the chest wall and a new local recurrence of the primary lesion in the left knee. Tolerance was excellent as it has been previously reported.^8,9 After the first cycle, 1 episode of hemoptysis was observed, without any hematologic disturbance, and resolved with symptomatic medication. The patient had a very important clinical improvement from the beginning of the treatment, better quality of life, performance status, and daily life activities. In addition, a significant reduction of lung masses can be shown by comparison of both ¹⁷⁷Lu-octreotate scan after the first single course.